Clinical Trial Update: Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of CBLB612 for neutropenia prophylaxis in breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CBLB612

Snippet

Sponsor: BioLab 612 LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED